

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/01, 31/015, 31/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/33492</b> <b>(43) International Publication Date:</b> 6 August 1998 (06.08.98)
<b>(21) International Application Number:</b> PCT/US98/02192 <b>(22) International Filing Date:</b> 5 February 1998 (05.02.98)  <b>(30) Priority Data:</b> 08/794,433 5 February 1997 (05.02.97) US  <b>(71) Applicant (for all designated States except US):</b> FOX CHASE CANCER CENTER [US/US]; 7701 Burholme Avenue, Philadelphia, PA 19111 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BROWN, Truman, R. [US/US]; 1651 E. Willow Grove Avenue, Laverock, PA 19038 (US). KAPPLER, Francis [US/US]; 3034 Diaston Street, Philadelphia, PA 19149 (US). SZWERGOLD, Ben- jamin [US/US]; P.O. 951, Hanover, NH 03755 (US). LAL, Sundeep [IN/US]; 1116 Highpoint Circle, Lansdale, PA 19446 (US). SU, Bangying [CN/US]; 1st floor, 711 Solly, Philadelphia, PA 19111 (US).  <b>(74) Agents:</b> HAGAN, Patrick, J. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103-2307 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS		
<b>(57) Abstract</b>  Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications, as well as methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS

Pursuant to 35 U.S.C. §202(c), it is hereby acknowledged that the U.S. Government has certain rights in the invention described herein, which was made in part with funds from the National Institutes of Health (Grant Nos. DK44050, DK50317 and DK50364).

**BACKGROUND OF THE INVENTION**

The present invention relates to therapeutic agents and their use for the treatment of diabetics and in particular for preventing, reducing or delaying the onset of diabetic complications and other disorders of related etiology. More particularly, the present invention relates to a class of enzyme inhibitors which inhibit the enzymatic conversion of fructose lysine (FL) to fructose-lysine-3-phosphate (FL3P), which is believed to be an important step in the biochemical mechanism leading to diabetic complications. This invention also relates to a method of assessing a diabetic patient's risk of experiencing diabetic complications, as well as a method of determining the efficacy of therapeutic intervention in preventing, reducing or delaying the onset of diabetic complications.

There are four particularly serious complications of diabetes, namely, diabetic nephropathy or kidney disease; diabetic retinopathy which causes blindness due to destruction of the retina; diabetic neuropathy involving the loss of peripheral nerve function; and circulatory problems due to capillary damage. Both retinopathy and

- 2 -

nephropathy are thought to be subsets of the general circulatory problems associated with this disease state. The role of microvascular dysfunction in late stage diabetes has been recently summarized (Tooke, Diabetes, 44: 721 (1995)). Throughout this disclosure, the terms "diabetes-associated pathologic conditions" and synonymous terms are meant to include the various well-known retinopathic, neuropathic, nephropathic, macroangiopathic, as well as other complications of diabetes.

The similarities between the pathologies arising from diabetes and those resulting from aging have been extensively reported. Studies have shown that many diabetes-associated pathologic conditions are clinically very similar to the pathologies normally associated with aging. It has been shown, for example, that in diabetes arteries and joints prematurely stiffen, lung elasticity and vital capacity prematurely decrease. Moreover, atherosclerosis, myocardial infarction and strokes occur more frequently in diabetics than in age-matched non-diabetic individuals. Diabetics are also more susceptible to infections, and are more likely to have hypertension, accelerated bone loss, osteoarthritis and impaired T-cell function at a younger age than non-diabetics.

The similarities between diabetes-associated pathologic conditions and aging would appear to suggest a common mechanistic rationale. A variety of mechanisms have been proposed as a common biochemical basis for both diabetes-associated pathologic conditions and aging. The hypothesis most strongly supported by data from human subjects is premised on a non-enzymatic glycosylation mechanism. This hypothesis states that the aging process and diabetes-associated pathologic conditions, such as

- 3 -

those described above, are caused, at least in part, by protein modification and cross-linking by glucose and glucose-derived metabolites via the Maillard reaction (Monnier et al., Proc. Natl. Acad. Sci. USA, 81: 583 (1984) and Lee et al., Biochem. Biophys. Res. Comm., 123: 888 (1984)). The modified proteins resulting from such glycosylation reactions are referred to herein as advanced glycation end product-modified proteins (AGE-proteins). It is widely accepted that 3-deoxyglucosone (3DG) is a key intermediate in the multi-step reaction sequence leading to AGE-protein formation. 3DG is a glucose-derived metabolite that can react with proteins leading to the cross-linking of both intracellular and extracellular proteins, such as collagen and basement membranes.

In the case of diabetic complications, the reactions that lead to AGE-proteins are thought to be kinetically accelerated by the chronic hyperglycemia associated with this disease. Evidence supporting this mechanism includes data showing that long-lived proteins such as collagen and lens crystallins from diabetic subjects contain a significantly greater AGE-protein content than do those from age-matched normal controls. Thus, the unusual incidence of cataracts in diabetics at a relatively early age is explainable by the increased rate of modification and cross-linking of lens crystalline. Similarly, the early onset of joint and arterial stiffening, as well as loss of lung capacity observed in diabetics is explained by the increased rate of modification and cross-linking of collagen, the key structural protein. Because these proteins are long-lived, the consequences of modification tend to be cumulative.

Another factor demonstrating cause and effect relationship between diabetic complications and

- 4 -

hyperglycemia is hyperglycemic memory. One particularly striking example of this phenomenon is the development of severe retinopathy in dogs that were initially diabetic, then treated to restore normal blood glucose levels. Although the dog eyes were histologically normal at the time of the treatment, over time diabetic retinopathy developed in these animals in spite of the normalized glucose concentrations (Engerman et al., Diabetes, 36: 808 (1987)). Thus, the underlying damage to the eyes irreversibly occurred during the period of early hyperglycemia, before clinical symptoms were evident.

Diabetic humans and animals have been shown to have higher than normal concentrations of early and late sugar modified AGE-proteins. In fact, the increase in AGE-proteins is greater than the increase in blood glucose levels. The concentration of AGE-proteins can be estimated by fluorescence measurement, as some percentage of sugar molecules rearrange to produce protein-bound fluorescent molecules.

The pathogenic role of AGE-proteins is not limited to diabetes. Protein glycation has been implicated in Alzheimer's disease (Harrington et al., Nature, 370: 247 (1994)). Increased protein fluorescence is also seen with aging. Indeed, some theories trace the aging process to a combination of oxidative damage and sugar-induced protein modification. Thus, a therapy that reduces AGE-protein formation may also be useful in treating other etiologically-similar human disease states, and perhaps slow the aging process.

It has generally been assumed that the formation of AGE-proteins begins with the reaction of a protein amino group and a sugar, primarily glucose. One typical literature citation states "The initial adduct formed by glycation of  $\epsilon$ -amino groups of lysine

- 5 -

residues is the Amadori compound, fructoselysine.... Glycation is an initial step in a complex series of reactions, known collectively as the Maillard or browning reaction, which ultimately leads to the formation of crosslinked, precipitated, oxidized, brown and fluorescent proteins". K.J. Knecht et al., Archives of Biochem. Biophys., 294: 130 (1992).

The formation of AGE-proteins from sugars is a multi-step process, involving early, reversible reactions with sugars to produce fructose-lysine containing proteins. These modified proteins then continue to react to produce irreversibly modified AGE-proteins. It is clear that AGE-proteins are not identical to proteins containing glycated-lysine residues, as antibodies raised against AGE-proteins do not react with fructose-lysine. It is also clear that AGE-proteins exist as multiple chemical species; however few have been identified. The chemical species ( $\epsilon$ -Amino-(carboxymethyl)lysine has been identified as one important final AGE-protein structure in recent studies (Reddy et al., Biochem., 34: 10872 (1995) and Ikeda et al., Biochemistry, 35: 8075 (1996)). This study failed to chemically identify another AGE-protein epitope that made up approximately 50% of the modified sites. A method of studying the kinetics of AGE-protein formation from ribose has recently been developed (Khalifah et al., Biochemistry, 35: 4645 (1996)). However, this study suggests that ribose may play an important physiological role in AGE-protein formation, supporting the relatively broad definitions of glycated-lysines and fructose-lysine provided below.

Other references point out the distinction between proteins containing glycated lysine residues and AGE proteins, "Equilibrium levels of Schiff-base and Amadori products are reached in hours and weeks,

- 6 -

respectively. The reversible, equilibrium nature of early glycosylation products is important, because it means that the total amount of such products, even on very long-lived proteins, reaches a steady-state plateau within a short period of time.....Since these early glycosylation products do not continue to accumulate on collagen and other stable tissue proteins over years in chronic diabetes, it is not surprising that their concentration does not correlate with either the presence or the severity of diabetic retinopathy...Some of the early glycosylation products on collagen and other long-lived proteins of the vessel walls do not dissociate, however. Instead, they undergo a slow, complex series of chemical rearrangements to form irreversible advanced glycosylation end products". M. Brownlee et al., New England Journal of Medicine, 318: 1315 (1988). The only route for production of these modified proteins which is described in the scientific literature involves an initial reaction between proteins and sugar molecules.

Numerous references point out that the formation of AGE-proteins occurs through a multi-step pathway and that 3-deoxyglucosone (3-DG) is a key intermediate in this pathway. M. Brownlee, Diabetes, 43: 836 (1994); M. Brownlee, Diabetes Care, 15: 1835 (1992); T. Niwa et al., Nephron, 69: 438 (1995); W.L. Dills, Jr., Am. J. Clin. Nutr., 58: S779 (1993); H. Yamadat et al., J. Biol. Chem., 269: 20275 (1994); N. Igaki et al., Clin. Chem., 36: 631 (1990). The generally accepted pathway for formation of 3DG from the reaction of sugars and proteins is illustrated in Figure 1. As can be seen in Figure 1, a sugar (glucose) molecule initially forms a Schiff base with a protein-lysine amino group (I). The resulting Schiff base then rearranges to produce fructose-lysine



- 7 -

modified proteins (II). The reactions leading up to (II) are freely reversible. (II) can rearrange to produce 3DG and free protein lysine. Subsequent reaction between 3DG and protein is the first irreversible step in AGE-protein formation.

Insofar as is known, it has never been reported that 3DG can be produced by alternative pathways, or indeed, that the major source of 3-DG is from an enzyme catalyzed metabolic pathway, rather than from the uncatalyzed reactions shown in Figure 1.

Diabetic patients have significantly more 3DG in serum than do non-diabetic patients ( $12.78 \pm 2.49 \mu\text{M}$  versus  $1.94 \pm 0.17 \mu\text{M}$ ). (Toshimitsu Niwa et al., *Nephron*, 69: 438 (1995)). Nonetheless, this toxic compound is found in normal healthy individuals. Thus, it is not surprising that the body has developed a detoxification pathway for this molecule. One of these reactions is catalyzed by aldehyde reductase which detoxifies 3DG by reducing it to 3-deoxyfructose (3DF) which is efficiently excreted in urine (Takahashi et al., *Biochem*, 34: 1433 (1995)). Another detoxification reaction oxidizes 3DG to 3-deoxy-2-ketogluconic acid (DGA) by oxoaldehyde dehydrogenase (Fujii et al., *Biochem. Biophys. Res. Comm.*, 210: 852 (1995)).

Results of studies to date show that the efficiency of at least one of these enzymes, aldehyde reductase, is adversely affected in diabetes. When isolated from normal rat liver, a fraction of this enzyme is partially glycated on lysines 67, 84 and 140 and has a low catalytic efficiency when compared with the normal, unmodified enzyme (Takahaski et al., *Biochem.*, 34: 1433 (1995)). Since diabetic patients have higher ratios of glycated proteins than normoglycemic individuals they are likely to have both higher levels of 3DG and a reduced ability to detoxify

- 8 -

this reactive molecule by reduction to 3DF.

The mechanism of aldehyde reductase has been studied. These studies determined that this important detoxification enzyme is inhibited by aldose reductase inhibitors (ARIs) (Barski et al., Biochem., 34: 11264 (1995)). ARIs are currently under clinical investigation for their potential to reduce diabetic complications. These compounds, as a class, have shown some effect on short term diabetic complications. However, they lack clinical effect on long term diabetic complications and they worsen kidney function in rats fed a high protein diet. As will appear hereinbelow, this finding is consistent with the newly discovered metabolic pathway for lysine recovery underlying the present invention. A high protein diet will increase the consumption of fructose-lysine, which undergoes conversion into 3DG by the kidney lysine recovery pathway. The detoxification of the resulting 3DG by reduction to 3DF will be inhibited by ARIs therapy; which consequently leads to an increase in kidney damage, as compared to rats not receiving ARIs. This is because inhibition of the aldose reductase by the ARIs would reduce availability of aldose reductase for reducing 3DG and 3DF.

The role of 3-DG in contributing to human disease has been previously investigated as will be appreciated from a review of the patents summarized below.

U.S. Patent 5,476,849 to Ulrich et al describes a method of inhibiting the formation of AGE-proteins using amino-benzoic acids and derivatives. These compounds presumably act by reacting with 3-DG and removing it from the system before it can react with proteins to begin the irreversible steps of AGE-protein formation.

- 9 -

U.S. Patents 4,798,583 and 5,128,360 to Cerami et al describes the use of aminoguanidine to prevent AGE-protein formation and diabetes-induced arterial wall protein cross-linking. Aminoguanidine  
5 was shown to react with an early glycosylation product. This early product is 3DG, as defined herein. These patents do not contemplate the possibility of inhibiting the formation of 3-DG. They focus exclusively on complexing this toxic molecule.

10 U.S. Patent 5,468,777 to France et al describes methods and agents for preventing the staining of teeth caused by the non-enzymatic browning of proteins in the oral cavity. Cysteine and cysteine derivatives are described as particularly useful in  
15 this application.

U.S. Patent 5,358,960 to Ulrich et al describe a method for inhibiting AGE-protein formation using aminosubstituted imidazoles. These compounds were shown to react with an early glycosylation  
20 product (3DG). No mention is made in this patent that a metabolic source of 3DG may exist. This patent envisions that 3DG is made exclusively as an intermediate in the non-enzymatic browning of proteins.

25 U.S. Patent 5,334,617 to Ulrich et al describes amino acids useful as inhibitors of AGE-protein formation. Lysine and other bifunctional amino acids are described as particularly useful in this regard. These amino acids are described as  
30 reacting with the early glycosylation product from the reaction of glucose and proteins. It appears that the early glycosylation product described in this patent is 3DG.

U.S. Patent 5,318,982 to Ulrich et al  
35 describes the inhibition of AGE-protein formation using as the inhibitory agent 1,2,4-triazoles. The

- 10 -

inhibitors described in this patent contain diamino-substituents that are positioned to react with and complex 3DG. The patent describes these compounds as reacting with an early glycosylation product (3DG  
5 as defined herein).

U.S. Patent 5,272,165 to Ulrich et al describes the use of 2-alkylidene-aminoguanidines as inhibitors of AGE-protein formation. The inhibitors described in this patent are said to be highly  
10 reactive with 3DG. No mention is made of inhibiting the metabolic formation of 3DG in this patent.

U.S. Patent 5,262,152 to Ulrich et al describes the use of amidrazones and derivatives to inhibit AGE-protein formation. The compounds  
15 described in this patent are  $\alpha$ -effect amines. W.P. Jencks, 3rd ed., McGraw Hill, New York. Compounds of this category are known to react with dicarbonyl compounds, e.g. 3DG.

U.S. Patent 5,258,381 to Ulrich et al describes the use of 2-substituted-2-imidazolines to inhibit AGE-protein formation. The compounds described in this patent contain adjacent amino groups that can readily react with 3DG.

U.S. Patent 5,243,071 to Ulrich et al describes the use of 2-alkylidene-aminoguanidies to inhibit AGE-protein formation. The compounds described in this patent are highly reactive with 3DG and function by complexing this reactive, toxic  
25 molecule.

U.S. Patent 5,221,683 to Ulrich et al describes the use of diaminopyridine compounds to inhibit AGE-protein formation. The diaminopyridine compounds described as particularly useful will react with 3DG to form a stable, six-member ring containing  
30 complex.

U.S. Patent 5,130,337 to Ulrich et al

- 11 -

describes the use of amidrazones and derivatives to inhibit AGE-protein formation. The inhibitors described in this patent are  $\alpha$ -effect amines which, as is known in the art, will rapidly react with 3DG and form stable complexes.

U.S. Patent 5,130,324 to Ulrich et al describes the use of 2-alkylidene-aminoguanidines to inhibit AGE-protein formation. The compounds described in this patent function by reacting with the early glycosylation product resulting from the reaction of glucose with proteins (3DG).

U.S. Patent 5,114,943 by Ulrich et al describes the use of amino-substituted pyrimidines to inhibit AGE-protein formation. The compounds described in this patent are said to rapidly react with and detoxify 3DG.

None of the above-mentioned patents suggest inhibition of the metabolic formation of 3DG as a means of therapeutic intervention to prevent diabetic complications. Indeed, none of these patents even suggest the involvement of an enzymatic pathway in the production of 3DG.

U.S. Patent 5,108,930 to Ulrich et al describes a method for detecting the levels of aminoguanidine in biological samples. This assay is described as having potential utility in determining kidney function by measuring the aminoguanidine elimination time. The principal utility intended for the assay method described in this patent is in the measurement of tissue levels of aminoguanidine, so that doses sufficient to inhibit AGE-protein formation can be maintained in animal and human studies. No mention is made in this patent of using urine 3DG, 3DF or DGA ratios to determine diabetics at risk for complications.

U.S. Patent 5,231,031 to Szwergold et al

- 12 -

describes a method for assessing the risk of diabetic-associated pathologic conditions and determining the efficacy of therapies for these complications. This patent describes the measurement  
5 of two phosphorylated compounds in erythrocytes of diabetic patients. These two compounds were not chemically identified in this patent. However, neither compound is 3DG or 3DF, whose levels are measured in urine in the diagnostic embodiment of the  
10 present invention.

Methods for monitoring metabolic control in diabetic patients by measurement of glycosylation end-products are known. The concentration of glycosylated hemoglobin is known to reflect mean blood glucose  
15 concentration during the preceding several weeks. U.S. Patent 4,371,374, issued to A. Cerami et al., describes a method for monitoring glucose levels by quantitation of the degradation products of glycosylated proteins, more specifically non-  
20 enzymatically glycosylated amino acids and peptides, in urine. This method purports to utilize the affinity of alkaline boronic acids for forming specific complexes with the coplanar cis-diol groups found in glycosylation end-products to separate and  
25 quantitate such end-products.

U.S. Patent 4,761,368 issued to A. Cerami describes the isolation and purification of a chromophore present in browned polypeptides, e.g., bovine serum albumin and poly-L-lysine. The  
30 chromophore, 2-(2-furoyl)-4(5)-2(furoyl)-1H-imidazole (FFI) is a conjugated heterocycle derived from the condensation of two molecules of glucose with two lysine-derived amino groups. This patent further describes the use of FFI in a method for measuring  
35 "aging" (the degree of advanced glycosylation) in a protein sample wherein the sample "age" is determined

- 13 -

by measuring the amount of the above-described chromophore in the sample and then comparing this measurement to a standard (a protein sample having an amount of FFI which has been correlated to the "age" of the sample).

There is a long-standing, unfilled need in existing treatment regimens of diabetic patients for effective means to identify those at risk of developing diabetes-associated pathologic conditions, to prevent, reduce or delay the onset of such conditions by therapeutic intervention and to determine the benefit of such therapeutic intervention.

#### SUMMARY OF THE INVENTION

The present invention arose from the discovery of a metabolic pathway that involves the enzyme-mediated conversion of FL to FL3P and produces relatively high concentrations of 3-deoxyglucosone (3DG) in organs affected by diabetes. Subsequent research into the biochemical function of this newly discovered pathway tends to indicate that it has an important role in the etiology of diabetic kidney disease. It is also suspected that this pathway contributes to the development of the various known diabetes-associated pathologic conditions.

This discovery has found practical application in the present invention which, in one aspect, provides a class of compounds which have enzyme inhibitory activity and are effective to inhibit the enzymatic conversion of fructose-lysine to fructose-lysine-3-phosphate. The relevant enzyme inhibitory activity of the compounds of the present invention is readily determinable by assay. The assay method comprises providing an aqueous solution of fructose-lysine, adenosine triphosphate (ATP), a

- 14 -

source of fructose-lysine-3-phosphate kinase and a compound of the present invention in an amount sufficient to demonstrate inhibitory activity, subjecting the resulting solution to conditions promoting the formation of fructose-lysine-3-phosphate and adenosine diphosphate as products of the interaction of the above-mentioned kinase, fructose-lysine and adenosine triphosphate, and measuring the production of at least one of such products, the compounds of the present invention reducing the amount of such products, as compared to an aqueous solution of the same relative amounts of fructose-lysine, adenosine triphosphate and source of fructose-lysine-3-phosphate kinase, without the addition of a compound of the present invention. The assay method just described is also within the scope of the present invention.

According to another aspect, the present invention provides a pharmaceutical preparation for preventing, reducing or delaying the onset of diabetic complications in a diabetic patient, comprising, as an active agent, a compound of the invention, as described above, and a pharmaceutically acceptable vehicle.

According to a further aspect of the present invention, there is provided a method for preventing, reducing or delaying the onset of diabetic complications in a patient at risk of developing same, which method comprises administering to the patient a compound of the present invention in an amount effective to inhibit the enzymatic conversion of fructose-lysine to fructose-lysine-3-phosphate. This same method may be used for the prevention or treatment of other etiologically-similar disease states, as will be further described hereinbelow.

According to still another aspect, the



- 15 -

present invention provides a method for assessing a diabetic patient's risk of experiencing a diabetes-associated pathologic condition. This method comprises administering to the patient a source of glycated-lysine residues in an amount providing a predetermined dose of the glycated-lysine residues, and measuring the ratio of 3-deoxyglucosone to 3-deoxyfructose in a biological sample obtained from the patient, with reference to the ratio of 3-deoxyglucosone to 3-deoxyfructose in a normal subject, i.e., a non-diabetic subject or one having no clinical symptoms of diabetes. The higher ratio of 3-deoxyglucosone to 3-deoxyfructose in the diabetic patient sample, in comparison to that of the asymptomatic subject is indicative that the diabetic patient is at higher risk of experiencing a diabetes-associated pathologic condition.

The present invention also provides a method for assessing the efficacy of therapeutic intervention in preventing diabetic complications. The method involves measuring the concentration of 3-deoxyglucosone, 3-deoxyfructose and fructose-lysine in biological samples obtained from a diabetic patient, both before and after initiation of the therapeutic intervention. The sum of the 3-deoxyglucosone and 3-deoxyfructose concentrations are then compared to the concentration of fructose-lysine in the samples. A decrease in the sum of 3-deoxyglucosone and 3-deoxyfructose concentrations relative to the fructose-lysine concentration in the biological sample taken after initiation of therapeutic intervention, as compared to the same concentrations measured in the biological sample taken before initiation of the therapeutic intervention, is indicative of the efficacy of the therapeutic intervention.

As yet another aspect of the present

- 16 -

invention, there is provided a method for apprising a diabetic person of the potential of a food product to contribute to the development of a diabetic-associated pathologic condition. This method involves measuring  
5 the content of glycated-lysine residues in the food product and providing this information to diabetic patients, e.g., on the package of the food product or in a publication intended for use by diabetics.

10 **BRIEF DESCRIPTION OF DRAWINGS**

FIGURE 1 shows the initial step involved in the multi-step reaction leading to irreversibly-modified AGE-proteins.

15 FIGURE 2 illustrates the reactions involved in the lysine recovery pathway.

FIGURE 3 is a graphical representation of a urinary profile showing the variation over time of  
20 3DF, 3DG and FL from a single individual fed 2 g. of FL and followed for 24 hours.

FIGURE 4 is a graphical representation of urinary excretion over time of 3DF from seven  
25 volunteers fed 2 g. of fructoselysine.

FIGURE 5 shows a graphical comparison of 3DF and N-acetyl- $\beta$ -glucosaminidase (NAG) between a group of control animals and an experimental group  
30 maintained on a feed containing 0.3% glycated protein.

FIGURE 6 is a graph showing the linear relationship between 3DF and 3DG levels in urine of rats fed either a control diet or one enriched in  
35 glycated protein.

- 17 -

FIGURES 7A and 7B are graphical representations of fasting levels of 3DG in the urine of normals and diabetic patients plotted against the fasting level of 3DF.

5

#### DETAILED DESCRIPTION OF THE INVENTION

The following definitions are provided to facilitate understanding of the present invention, as described in further detail hereinbelow:

10

1. Glycated-Lysine Residues - The expression "glycated lysine residues", as used herein, refers to the modified lysine residue of a stable adduct produced by the reaction of a reducing sugar and a lysine-containing protein.

15

The majority of protein lysine residues are located on the surface of proteins as expected for a positively charged amino acid. Thus, lysine residues on proteins which come in contact with serum, or other biological fluids, can freely react with sugar molecules in solution. This reaction occurs in multiple stages. The initial stage involves the formation of a Schiff base between the lysine free amino group and the sugar keto-group. This initial product then undergoes the Amadori rearrangement, to produce a stable ketoamine compound.

25

This series of reactions can occur with various sugars. When the sugar involved is glucose, the initial Schiff base product will involve imine formation between the aldehyde moiety on C-1 of the glucose and the lysine  $\epsilon$ -amino group. The Amadori rearrangement will result in formation of lysine coupled to the C-1 carbon of fructose, 1-deoxy-1-( $\epsilon$ -aminolysine)-fructose, herein referred to as fructose-lysine or FL.

30

35

Similar reactions will occur with other aldose sugars, for example galactose and ribose

- 18 -

(Dills, Am. J. Clin. Nutr., 58: S779 (1993)). For the purpose of the present invention, the early products of the reaction of any reducing sugar and the  $\epsilon$ -amino residue of protein lysine are included within the meaning of glycated-lysine residue, regardless of the exact structure of the modifying sugar molecule.

Also, the terms glycated-lysine residue, glycated protein and glycosylated protein or lysine residue are used interchangeably herein, which is consistent with current usage in scientific journals where such expressions are often used interchangeably.

2. Fructose-lysine - The term "fructose-lysine" (FL) is used herein to signify any glycated-lysine, whether incorporated in a protein/peptide or released from a protein/peptide by proteolytic digestion. This term is specifically not limited to the chemical structure commonly referred to as fructose-lysine, which is reported to form from the reaction of protein lysine residues and glucose. As noted above, lysine amino groups can react with a wide variety of sugars. Indeed, one report indicates that glucose is the least reactive sugar out of a group of sixteen (16) different sugars tested (Bunn et al., Science, 213: 222 (1981)). Thus, tagatose-lysine formed from galactose and lysine, analogously to glucose is included wherever the term fructose-lysine is mentioned in this description, as is the condensation product of all other sugars, whether naturally-occurring or not. It will be understood from the description herein that the reaction between protein-lysine residues and sugars involves multiple reaction steps. The final steps in this reaction sequence involve the crosslinking of proteins and the production of multimeric species, known as AGE-proteins, some of which are fluorescent. Proteolytic

- 19 -

digestion of such modified proteins does not yield lysine covalently linked to a sugar molecule. Thus, these species are not included within the meaning of "fructose-lysine", as that term is used herein.

5                   3.   Fructose-lysine-3-phosphate - This compound is formed by the enzymatic transfer of a high energy phosphate group from ATP to FL. The term fructose-lysine-3-phosphate (FL3P), as used herein, is meant to include all phosphorylated fructose-lysine  
10                   moieties that can be enzymatically formed whether free or protein-bound.

                  4.   Fructose-lysine-3-phosphate kinase - This term refers to one or more proteins which can enzymatically convert FL to FL3P, as defined above,  
15                   when additionally supplied with a source of high energy phosphate.

                  5.   3-Deoxyglucosone - 3-Deoxyglucosone (3DG) is the 1,2-dicarbonyl-3-deoxysugar (also known as 3-deoxyhexulosone) which is formed upon breakdown  
20                   of FL3P to yield free lysine and inorganic phosphate. For purposes of the present description, the term 3-deoxyglucosone is intended to include all possible dicarbonyl sugars which are formed upon breakdown of FL3P, having the broad definition of FL3P stated  
25                   above.

                  6.   FL3P Lysine Recovery Pathway - A lysine recovery pathway exists in human kidney, and possibly other tissues, which regenerates unmodified lysine as a free amino acid or incorporated in a  
30                   polypeptide chain. As will be further explained below, this pathway is an important factor contributing to the complications of diabetes.

                  7.   AGE-Proteins - The term "AGE-proteins" (Advanced Glycation End-product modified proteins) has  
35                   been used in scientific journals, and is used herein, to refer to the final product of the reaction between

- 20 -

sugars and proteins (Brownlee, Diabetes Care, 15: 1835 (1992) and Niwa et al., Nephron, 69: 438 (1995)). It is clear that the reaction, for example, between protein lysine residues and glucose does not stop with the formation of fructose-lysine. FL can undergo multiple dehydration and rearrangement reactions to produce non-enzymatic 3DG, which reacts again with free amino groups, leading to cross-linking and browning of the protein involved. Indeed, there is reasonable evidence that 3DG, as defined hereinabove, is a central intermediate in this modification reaction.

9. "Glycated Diet" - As used herein, this expression refers to any given diet in which a percentage of normal protein is replaced with glycated protein. The expression "glycated diet" and "glycated protein diet" are used interchangeably herein.

At least some, and possibly all, of the complications of diabetes are due to the covalent modification of proteins by glucose and other reactive sugars. M. Brownlee, Diabetes, 43: 836 (1994). As noted above, diabetic humans and animals have been shown to have higher concentrations of sugar modified proteins than normal. In fact, the increase in diabetes-associated AGE-proteins is greater than the increase in blood glucose levels.

Previously, it had been generally accepted that the origin of 3DG *in vivo* was from the decomposition of proteins containing glycated lysine residues. It had also been commonly believed that these glycated-lysines could not be used as an amino acid source. As will appear hereinbelow, this previous belief was incorrect.

As mentioned above, the present invention evolved from the discovery of a previously unknown metabolic pathway which produces 3DG in an enzyme-

- 21 -

catalyzed reaction. This enzymatic pathway is capable of enzymatic inhibition, thereby reducing the production of toxic 3DG.

During the course of a series of studies on diabetic kidneys, examination of  $^{31}\text{P}$  NMR spectra from perchloric acid extracts of kidneys from streptozotoxin induced diabetic rats revealed an unusual new peak in the NMR spectrum. Previous studies by the present inventors had demonstrated the presence of fructose-3-phosphate in rat lens and human erythrocytes (A. Petersen et al., *Biochem. J.*, 284: 363-366 (1992); Lal et al., *Arch. Biochem. Biophys.*, 318: 191 (1995); Szwergold et al., *Science*, 247: 451 (1990) and Lal et al., *Investigative Ophthalmology and Visual Science*, 36(5): 969 (1995)). Earlier studies had identified other unusual phosphorylated sugars in rat lens (Szwergold et al., *Diabetes*, 44: 810 (1995) and Kappler et al., *Metabolism*, 44: 1527 (1995)). Thus it was reasonable to assume that this newly identified peak was another phosphorylated sugar. Further extensive laboratory investigation revealed that this new compound was not a simple sugar, but rather fructose-lysine phosphorylated on the 3 position of the fructose component.

This identification was confirmed in two ways. Authentic fructose-lysine-3-phosphate (FL3P) was synthesized by the procedure disclosed in Example 2, below, and shown to co-resonate in the  $^{31}\text{P}$  NMR spectrum with the peak in diabetic rat kidneys. Synthetic fructose-lysine was also injected into non-diabetic rats. These rats showed a substantial increase in the levels of FL3P in their kidneys following this injection.

Two experiments were conducted to demonstrate that FL3P is derived directly from FL in an enzyme catalyzed reaction. Fructose-lysine labeled

- 22 -

with deuterium at the C3 position of the fructose moiety was synthesized and injected into rats. Three hours after injection, the kidneys of these rats were removed and extracted with perchloric acid. NMR spectroscopy revealed that the FL3P material isolated from these rats contained the deuterium label at the C3 position of the fructose moiety. In addition, rat kidney homogenates demonstrate the ability to produce FL3P in a reaction requiring both ATP and fructose-lysine. This last-mentioned experiment confirms the presence of a specific FL3P kinase, as no FL3P is formed when only fructoselysine and ATP are incubated together under physiological conditions. Further experiments which involved the fractionation of kidney cortex have demonstrated that this kinase activity is not distributed uniformly in the kidney but is concentrated in the proximal tubular region, which is one of the earliest anatomical sites to demonstrate damage in human and animal diabetic kidneys.

FL3P is not stable in aqueous solution. It rapidly degrades to form 3DG, lysine and inorganic phosphate. This reaction also occurs in vivo. It is not currently known if the degradation of FL3P in vivo is a spontaneous or enzyme catalyzed reaction. It is strongly suspected, however, that enzymatic catalysis is involved, as the production of 3DG from fructose-lysine occurs very rapidly in intact kidney.

The reaction steps in the FL3P lysine recovery pathway are presented in Figure 2. In the first step, fructose-lysine and ATP react to form fructose-lysine-3-phosphate (FL3P) and ADP in a reaction catalyzed by FL3P kinase. Phosphorylation occurs on the 3-position of the fructose moiety, leading to destabilization of the fructoselysine molecule. The resulting FL3P then decomposes to form 3-deoxyglucosone (3DG), inorganic phosphate, and



- 23 -

unmodified, free, reusable lysine, which is available for utilization in protein synthesis. Aldehyde reductase detoxifies 3DG by reduction to 3-deoxyfructose (3DF), which is excreted in urine.

5           Although Figure 2 illustrates this pathway using the most prevalent glycated-lysine, fructose-lysine, it will be readily apparent to those skilled in the art that a wide variety of similar molecules can flux through this pathway. Indeed, as will be  
10 explained in further detail below, the substrate selectivity of the FL3P lysine recovery pathway is quite broad, warranting the broad definition of the terms given above.

          Additional experiments have shown that the  
15 lysine recovery pathway is found in a wide variety of animal species, including sheep, pig, dog, rabbit, cow, mice and chicken. This pathway is also present in humans. The ubiquitous presence of the FL3P lysine recovery pathway can be understood, given that lysine  
20 is an essential amino acid which is present in relatively low concentrations in most foods. In addition, an appreciable percentage of the lysine residues in food will exist in the glycated form and the proportion of this modified lysine will increase  
25 when the food is cooked. Since these glycated lysine residues can not be utilized for protein synthesis, a recovery pathway for lysine is of great utility and affords a selective advantage to organisms which possess it.

30           Diabetes has two effects on the lysine recovery pathway. Blood proteins contain higher concentrations of glycated-lysines when isolated from diabetics than from non-diabetic individuals. Thus, diabetics are subject to greater flux through the  
35 lysine recovery pathway than non-diabetics. Additionally, from preliminary observations on the

- 24 -

ratios of 3DG and 3DF in the urine of diabetics and normals, diabetics appear to have a reduced ability to detoxify 3DG that is produced via this pathway. These two factors combine to produce higher urinary  
5 concentrations of 3DG in diabetics (See Figure 7; also Lal et al., Arch. Biochem. and Biophys., 342(1): 254-60 (1997)).

The agents involved in the lysine recovery pathway have been identified in other tissues besides  
10 kidney, specifically red blood cells, lens, and peripheral nerve tissues. All of these tissues are affected by the complications of diabetes. The location in red blood cells correlates with the microvascular complications of diabetes, e.g.,  
15 diabetic retinopathy, the kidney location correlates with diabetic nephropathy, while the location in peripheral nerve correlates with diabetic peripheral neuropathy. These agents are also found in pancreas. Experiments are in progress to determine the presence  
20 of these agents in skin. If found to be present, it is believed that their deleterious effects may be ameliorated by a topical treatment using the inhibitory compounds of the invention in a suitable vehicle to prevent collagen crosslinking, and thereby  
25 improve skin elasticity.

Experiments have been conducted that tend to prove that humans produce both 3DG and 3DF from orally ingested proteins containing glycated-lysine residues. These experiments, which are described in detail  
30 below, convincingly demonstrate that the lysine recovery pathway exists in humans. These experiments also shed light on a puzzling phenomenon, namely, that some diabetics develop diabetic complications, while others, even those in poor glycemic control, do not  
35 develop such complications. The reason for this phenomenon is apparent from the data presented herein.

- 25 -

Diabetics have a differing ability to detoxify 3DG. A subset of the diabetic population appears to have relatively higher aldehyde reductase activities than does the majority of diabetics. Consequently, these individuals are capable of handling the increased flux through the lysine recovery pathway by efficiently detoxifying the higher than normal level of 3DG. Others with impaired capacity are less able to detoxify their elevated 3DG levels, and consequently are at higher risk of developing diabetic complications.

As will be described in more detail below, it has been experimentally demonstrated that stimulation of the lysine recovery pathway can occur through the use of a glycated protein diet. As was the case with FL above, elevation of FL3P, 3DG and 3DF was observed in test animals that were fed the glycated protein diet.

The enzyme inhibitor compounds of the invention block the lysine recovery pathway, preventing formation of toxic 3DG from FL3P.

Described below is a set of extensive criteria that a suitable enzyme inhibitor should display for use in the practice of this invention, as well as certain tests for determining if any putative inhibitor meets these criteria. Candidate kinase inhibitors for use in accordance with this invention may be natural products isolated from plants or microorganisms. Alternatively, they may be synthetic molecules derived from the rational knowledge of the enzymatic reaction and its mechanism. Inhibitors may also be synthesized by combinatorial methods. Combinatorial libraries may be generated from a random starting point. Furthermore, combinatorial methods can be utilized to generate a wide variety of compounds related to previously identified inhibitors

- 26 -

of the target FL3P kinase.

Regardless of the source of the putative inhibitor, compounds that do not meet all of the criteria listed below are not considered useful therapeutic agents capable of inhibiting the lysine recovery pathway and thereby preventing, reducing or delaying the onset of diabetic complications or disorders of related etiology.

1. The inhibitor should be a small molecule and readily taken up by cells. In order to meet this criteria, the inhibitor must have a molecular weight of less than 2,000 and more ideally approximately 1,000 daltons or less.

2. The inhibitor must show competitive, noncompetitive, irreversible or suicide inhibition of the FL3P kinase. If the inhibitor is a competitive or noncompetitive inhibitor, the inhibition constant,  $K_i$ , must be less than about 1 mM. Ideally, it must be less than 100  $\mu$ M and more ideally, about 40  $\mu$ M or less. If the inhibitor shows suicide or other irreversible inhibition, this requirement for inhibition constant is rendered moot.

3. The inhibitor must be both soluble in aqueous solution and stable in aqueous solution at physiological pH. The requirement for solubility is met only if the inhibitor, or a salt of the inhibitor, is soluble in physiological saline or serum at a concentration equal to or greater than 10  $\mu$ M. This stability requirement is met only if a solution of inhibitor dissolved in physiological saline at 37°C retains greater than 50% of its activity after incubation for one hour. Ideally, the inhibitor must retain greater than 50% activity upon incubation for one day or more.

4. The inhibitor must show acceptable pharmacokinetics. That is, it must remain at a


- 27 -

therapeutically effective concentration for at least one hour following administration of the agent. Ideally, it should maintain effective concentration for at least eight hours. More ideally, once per day dosing should be all that is necessary in order to maintain a therapeutic concentration of the inhibitor. This requirement does not mean that the inhibitor must be able to establish a therapeutic concentration after the first dose. Numerous examples of successful pharmaceuticals exist where medical efficacy is seen only upon prolonged dosing. The criterion does mean that, once an efficacious concentration is reached, this concentration should be able to be maintained for greater than one hour following the last administration of medication. A test for therapeutic efficacy is described herein.

5. The inhibitor must be non-toxic. This criteria requires that the inhibitor not demonstrate human toxicity when administered at the therapeutic dose. Ideally, toxicity should not be evident when the inhibitor is present at blood and/or target tissue levels of twice that needed for therapeutic effect. More ideally, there should be no appreciable toxicity at levels 6 or more times the therapeutic range. Diabetic complications can only be prevented by long term inhibitor treatment. Therefore, the requirement for non-toxicity must include both acute toxicity and chronic toxicity that may become evident over extended, long term use. Toxicity of candidate molecules can be readily assessed using well established animal studies. Human toxicity is assessed in stage one clinical trials.

- 28 -


Included among the compounds useful in the practice of this invention are those of the formula:



wherein X is -NR'- or -O-, R' being selected from the group consisting of H, and linear or branched chain alkyl group (C<sub>1</sub>-C<sub>4</sub>) and an unsubstituted or substituted aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>); R is a substituent selected from the group consisting of H, an amino acid residue, a polyaminoacid residue, a peptide chain, a linear or branched chain aliphatic group (C<sub>1</sub>-C<sub>8</sub>), which is unsubstituted or substituted with at least one nitrogen- or oxygen-containing substituent, a linear or branched chain aliphatic group (C<sub>1</sub>-C<sub>8</sub>), which is unsubstituted or substituted with at least one nitrogen- or oxygen-containing substituent and interrupted by at least one -O-, -NH-, or -NR"- moiety, R" being linear or branched chain alkyl group (C<sub>1</sub>-C<sub>6</sub>) and an unsubstituted or substituted aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>), with the proviso that when X represents -NR'-, R and R', together with the nitrogen atom to which they are attached, may also represent a substituted or unsubstituted heterocyclic ring having from 5 to 7 ring atoms, with at least one of nitrogen and oxygen being the only heteroatoms in said ring, said aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>) and said heterocyclic ring substituents being selected from the group consisting of H, alkyl (C<sub>1</sub>-C<sub>6</sub>), halogen, CF<sub>3</sub>, CN, NO<sub>2</sub> and -O-alkyl (C<sub>1</sub>-C<sub>6</sub>); R<sub>1</sub> is a polyol moiety having 1 to 4 linear carbon

- 29 -

atoms, Y is either a carbonyl moiety



5

selected from the group consisting of -H, -O-alkyl ( $\text{C}_1$ - $\text{C}_6$ ), -halogen - $\text{CF}_3$ , -CN, -COOH, and - $\text{SO}_3\text{H}_2$ , and optionally -OH; and the isomers and pharmaceutically acceptable salts of said compound.

10

Illustrative examples of nitrogen- or oxygen-containing "R" substituents include those derived from  $\gamma$ -amino- $\alpha$ -hydroxy butyric acid ( $-(\text{CH}_2)_2\text{-CHOH-COOH}$ ), 1,2,4 triaminobutane ( $-(\text{CH}_2)_2\text{-CHNH}_2\text{-CH}_2\text{NH}_2$ ), 3,6-diamino-5-hydroxyheptanoic acid ( $-\text{CH}_2\text{-CH(OH)-CH}_2\text{-CH(NH}_2\text{)-CH}_2\text{-COOH}$ ), and the like.

15

The structure of formula I has asymmetric centers and may occur as racemates, racemic mixtures and various stereoisomers, all of such isomeric forms being within the scope of this invention, as well as mixtures thereof.

20

Although certain of the compounds having the structure of formula I, above, were previously known, others are believed to be novel and as such are within the scope of the present invention, as is the use of all of the compounds of formula I for inhibiting the enzyme-catalyzed production of 3DG *in vivo*.

25

Inhibitors of the above formula may be prepared by reacting the appropriate sugar, e.g., glucose, galactose, mannose, ribose, xylose, or derivative thereof, with an amino acid or other appropriate primary or secondary amine to yield inhibitors having a carbonyl moiety (i.e.,  $\text{Y}=\text{C}(=\text{O})$ ). Alternatively, sugars, such as glucose, galactose, mannose, ribose, xylose, or the like, may be reacted with an amino- or hydroxyl-substituted reactant of the type described herein in the presence of an agent, such as  $\text{NaBH}_3\text{CN}$ , that selectively reduces the

35

- 30 -

Schiff-base intermediate to an amine, thereby producing an inhibitor having an alcohol moiety (i.e.,  $Y = -CH(-OH)-$ ). The reactive moiety of an amino acid reactant, when used, may be the amine group on the  
5 alpha-carbon, or the amine group or hydroxyl group on the acid side chain. Suitable amino acids encompass the essential amino acids. Specific examples include without limitation, glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, aspartic  
10 acid, phenylalanine, tyrosine, histidine and tryptophan. Other suitable reactants are from the broader class of aminocarboxylic acid, for example, pyroglutamic acid, beta-alanine, gamma-aminobutyric acid, epsilon-amino caproic acid and the like. N-acyl  
15 derivatives of the above-mentioned amino acids, such as formyl lysine, may also be used if desired.

Other appropriate reactants include, without limitation, unsubstituted or substituted aryl ( $C_6-C_{10}$ ) compounds, wherein the substituent may be alkyl ( $C_1-$   
20  $C_3$ ), alkoxy, carboxy, nitro or halogen groups, unsubstituted or substituted alkanes, wherein the substituent may be at least one alkoxy group; or unsubstituted or substituted nitrogen-containing heterocyclic compounds, wherein the substituents may  
25 be alkyl ( $C_1-C_3$ ), aryl ( $C_6-C_{10}$ ), alkoxy, carboxy, nitro or halogen groups. Illustrative examples of the last-mentioned group of reactants include m-methyl-, p-methyl-, m-methoxy-, o-methoxy- and m-nitro-aminobenzenes, o- and p-aminobenzoic acids; n-propylamine, n-butylamine, 3-methoxypropylamine;  
30 morpholine and piperidine.

Representative inhibitor compounds having the above formula are set forth in the attached Table A. Examples of known compounds that may be used as  
35 inhibitors in practicing this invention include, without limitation, meglumine, sorbitol lysine and



- 31 -

mannitol lysine.

The inhibitor compounds described herein can form pharmaceutically acceptable salts with various inorganic or organic acids or bases. Suitable bases  
5 include, e.g., alkali metal salts, alkaline earth metal salts, ammonium, substituted ammonium and other amine salts. Suitable acids include, e.g., hydrochloric acid, hydrobromic acid and methanesulfonic acid.

10 The pharmaceutically acceptable salts of the compounds of formula I can be prepared following procedures which are familiar to those skilled in the art.

The ability of a compound to inhibit the  
15 FL3P kinase can be determined using a wide variety of kinase activity assays. One useful assay involves incubating the potential inhibitor with fructose-lysine and ATP in the presence of kidney homogenate or other enzyme source. A solution of the  
20 assay components is prepared, which typically contains 1 millimole or less of the inhibitor compound of this invention, an amount of fructose lysine (FL) in the range of 1-10 millimoles, an amount of ATP in the range of 0.1-10 millimoles and an amount of the enzyme  
25 source which is sufficient to convert FL to fructose lysine-3-phosphate. The incubation should be conducted within a pH range of 4.5 to 9.5 and ideally at neutral or near neutral pH. The incubation should be carried out at a temperature that is compatible  
30 with enzyme activity, between 4° and 40°C. Ideally, the incubation is carried out at physiological temperature. After incubation, the reaction is stopped by acid precipitation of the protein and the production of FL3P measured by <sup>31</sup>P-NMR spectroscopy.  
35 FL3P production will be reduced or eliminated in samples containing an inhibitor compound when compared

- 32 -

to control samples that are free of inhibitor.

Other assays have utility for the rapid determination of enzyme inhibition. One such assay involves the use of fructose-lysine and  $\gamma$ -labelled  $^{32}\text{P}$  or  $^{33}\text{P}$ -ATP. Since FL3P does not bind to Dow-1 but ATP and most other phosphates do, it is possible to separate the product FL3P from the remaining reaction mixture by passing the assay solution through a column of Dow-1 resin after a predetermined reaction time, typically 10 minutes. The resultant solution is added to a container of scintillation liquid, e.g., Ecoscint A, and counted to determine the amount of radioactivity produced.

As it is difficult to obtain large quantities of human tissue, it is preferable to use a recombinant version of the kinase that is cloned into an expression system, such as E. Coli. The cloned kinase can be readily obtained from the "shotgun" cloning of tissue specific cDNA libraries. Such libraries are readily available from commercial sources. For example they may be obtained from Clontech, Palo Alto, CA. The shotgun cloning envisioned may be performed using the lambda cloning system commercially available from Stratagen, located in San Diego, California. This cloning kit contains detailed instructions for its use.

The pharmaceutical preparations of the present invention comprise one or more of the compounds described above, as the active ingredient, in combination with a pharmaceutically acceptable carrier medium or auxiliary agent.

These ingredients may be prepared in various forms for administration, including both liquids and solids. Thus, the preparation may be in the form of tablets, caplets, pills or dragees, or can be filled in suitable containers, such as capsules, or, in the

- 33 -

case of suspensions, filled into bottles. As used herein, "pharmaceutically acceptable carrier medium" includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface  
5 active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Representative examples of suitable carrier media include gelatine, lactose,  
10 starch, magnesium stearate, talc, vegetable and animal fats and oils, gum, polyalkylene glycol, or the like. Remington's Pharmaceutical Sciences, Fifteenth Edition, E.W. Martin (Mack Publishing Co., Easton, PA 1975) discloses various carriers used in formulating  
15 pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the enzyme inhibitors of the invention, such as by producing any undesirable biological effect or  
20 otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical preparation, its use is contemplated to be within the scope of this invention.

In the pharmaceutical preparations of the  
25 invention, the active agent(s) may be present in an amount of at least 5% and generally not more than 98% by weight, based on the total weight of the preparation, including carrier medium and/or auxiliary agent(s), if any. Preferably, the proportion of  
30 active agent varies between 65% - 95% by weight of the composition.

Preferred supplementary active agents are compounds that bind to 3DG *in vivo*. This class of compounds includes, without limitation,  
35 aminoguanidine, amino benzoic acid and derivatives thereof, cysteine and derivatives thereof, amino-

- 34 -

substituted imidazoles, 1,2-disubstituted  
benzimidazoles, substituted 1,2,4-triazoles,  
diaminopyridine and derivatives thereof, amino-  
substituted pyrimidines, aminoalcohols, diamines and  
5 the like. Anti-hypertensive drugs, including  
particularly the angiotensin-converting enzyme (ACE)  
inhibitors, may also be included as supplementary  
active agents in the pharmaceutical preparations of  
this invention.

10 Auxiliary agents, such as compounds that  
will protect the active compound from acid destruction  
in the stomach or facilitate the absorption of the  
active compound into the bloodstream can also be  
incorporated into the pharmaceutical preparation, if  
15 necessary or desirable. Such auxiliary agents may  
include, for example, complexing agents such as borate  
or other salts which partially offset the acid  
conditions in the stomach, and the like. Absorption  
can be increased by delivering the active compound as  
20 the salt of a fatty acid (in those cases where the  
active compound contains one or more basic functional  
groups).

The compounds of the invention, along with  
any supplementary active ingredient(s) may be  
25 administered, using any amount and any route of  
administration effective for inhibiting the FL3P  
lysine recovery pathway. Thus, the expression  
"therapeutically effective amount", as used herein,  
refers to a nontoxic but sufficient amount of the  
30 enzyme inhibitor to provide the desired therapy to  
counteract diabetic complications or to inhibit the  
metabolic production of 3DG for other medical reasons,  
such as reducing the effects of aging or other human  
disease states where AGE-Protein formation has a  
35 causative role. The exact amount required may vary,  
depending on the species, age, and general condition

- 35 -

of the patient, the nature of the complications, the particular enzyme inhibitor and its mode of administration, and the like.

The compounds of the invention are preferably formulated in dosage form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to a physically discrete unit of enzyme inhibitor appropriate for the patient to be treated. Each dosage should contain the quantity of active material calculated to produce the desired therapeutic effect either as such, or in association with the selected pharmaceutical carrier medium. Typically, the compounds of the invention will be administered in dosage units containing from about 1 mg to about 2,500 mg of the compound, by weight of the preparation, with a range of about 5 mg to about 250 mg being preferred.

The compounds of the invention may be administered orally, parenterally, such as by intramuscular injection, intraperitoneal injection, intravenous infusion or the like, depending on the nature of the diabetic complication being treated. The compounds of the invention may be administered orally or parenterally at dosage levels of about 0.7  $\mu$ g to about 20 mg and preferably from about 30  $\mu$ g to about 3.5 mg/kg, of patient body weight per day, one or more times a day, to obtain the desired therapeutic effect.

Orally active enzyme inhibitors are particularly preferred, provided the oral dose is capable of generating blood and/or target tissue levels of the inhibitor that are therapeutically active. Those skilled in the art can readily measure the levels of a small molecule inhibitor in deproteinized samples of blood, kidney and other target tissues. The concentration of inhibitor in

- 36 -

these samples can be compared with the predetermined inhibitory constant. Tissue levels that are far below the inhibitory constant suggest a lack of therapeutic activity. In the case of irreversible inhibitors, this lack can be confirmed or refuted by assay of the FL3P kinase levels in the respective tissue. In all cases, therapeutic activity can be assessed by feeding the human or animal subject a food rich in glycated lysine residues or fructose-lysine and measuring the amount of 3DG and 3DF in their urine, both before and after feeding. Subjects that have therapeutically active inhibitor in their systems will experience decreased secretion of both 3DG and 3DF and increased urinary secretion of fructose-lysine when compared to levels secreted by these same subjects prior to inhibitor therapy as will be described in further detail hereinbelow.

The compounds of the invention will typically be administered once per day or up to 4-5 times per day, depending upon the exact inhibitor chosen. While a dosing schedule of once-a-day is preferred, diabetic patients are accustomed to paying close attention to their disease state, and so will readily accept more frequent dosing schedules if required, so as to deliver the above-mentioned daily dosage. However, the exact regimen for administration of the compounds and compositions described herein will necessarily be dependent on the needs of the individual patient being treated, the type of treatment administered and the judgment of the attending physician. As used herein, the term "patient" includes both humans and animals.

The inhibitor compounds described herein are useful in counteracting diabetic complications, especially diabetic nephropathy which affects greater than forty percent of diabetics and is the primary

- 37 -

cause of end stage renal disease requiring dialysis and transplantation. In addition, these inhibitors may be used for the prevention or treatment of other pathological conditions attributable to the formation of AGE-proteins, such as hypertension, stroke, neurodegenerative disorders, e.g., senile dementia of the Alzheimers type, circulatory disease, atherosclerosis, osteoarthritis, cataracts and the general debilitating effects of aging.

Preliminary experiments have shown that serious adverse health effects result from stimulation of the lysine recovery pathway through long-term consumption of glycated proteins. As was the case with FL, elevation of FL3P, 3DG and 3DF was observed in test animals that were fed a glycated protein diet. See Table B. After eight months of such a diet clear evidence of kidney pathology, resembling that found in diabetic kidneys, was seen in the animals on the glycated protein diet, as described further in Example 10, below. Transient elevation of 3DG and 3DF levels were also observed in the urine of human volunteers who ate a small amount of the glycated protein.

TABLE B

% Glycated Protein	FL3P conc. (nM-in Kidney)	3DG/3DF concs ( $\mu$ M-in plasma)
0	97	1.4/0.05
1	295	-
2.5	605	-
5	937	-
10	1066	3.6/0.12
20	1259	5.2/0.14
30	1267	6.2/0.28

- 38 -

Since stimulation of the newly discovered lysine recovery pathway leads to substantial increases in systemic 3DG levels, an investigation was carried out to determine whether a glycated diet would cause significant effects on pregnancy. The results obtained so far suggest there is a very strong effect due to this pathway, as will appear in the examples that follow.

Furthermore, it is well known that in susceptible strains of rats and mice the diets on which the animals are maintained in early life (following weaning), can have a marked effect on the incidence of type 1 diabetes, with the incidence ranging from 10% to 90%. Considerable effort has been put into investigating this phenomenon over the last 10 years. See, for example, Diabetes, 46(4): 589-98 (1997) and Diabetes Metab. Rev., 12(4): 341-59 (1996), and references cited therein. An investigation has been undertaken by certain of the present inventors with respect to two diets which are at the extremes for induction of diabetes. AIN-93 (Dyets, Inc.) causes the least incidence of diabetes and produces the lowest ratio of urinary 3DF/creatinine (1.0) yet observed. Purina 500 induces the highest incidence of diabetes and produces a 2.5 fold increase in the 3DF/creatinine ratio. Since FL3P, 3DG and 3DF were observed in the pancreas of rats, it is likely that fructoselysine kinase and the metabolites of this metabolic pathway are involved in the development of Type I diabetes. Animals which are susceptible to this type of diabetes (a useful model of insulin dependent or Type I diabetes in humans) have an abnormal immune system which makes them sensitive to an unknown antigen which develops in the  $\beta$ -cells of the pancreas, resulting in an autoimmune attack by the animal's own immune system on its  $\beta$ -cells. this



- 39 -

results in their subsequent destruction, thereby depriving the animal of the ability to make insulin. It is well known that 3DG reacting with proteins can make new antigenic sites. Thus, the source of the  
5 antigenic properties of the various diets appears to be the 3DG created by the decomposition of fructoselysine-3-phosphate in the pancreas.

Also, because 3DG is known to interact with amines generally, it may be able to interact with DNA  
10 and show mutagenic and carcinogenic potential, as well as crosslink proteins.

The discovery of the FL3P lysine recovery pathway makes it practical, for the first time, to differentiate the diabetic population and to determine  
15 which subset of the population is likely to develop to diabetic complications. This determination can be conveniently carried out on a biological fluid of the test subject, such as urine, blood fractions (particularly plasma or serum), lymph fluid,  
20 interstitial fluid or the like:

After an overnight fast, a human subject is fed a food source containing a relatively high concentration of glycated-lysine residues. By way of example, this food can be in the form of a  
25 casein/sugar "cookie", such as described in Example 5, below, or some other suitable source of glycated-lysines or synthetic fructose-lysine. When proteins containing glycated-lysine residues are utilized, the content of glycated-lysine should be preferably  
30 between 0.02 and 10% of total protein amino acid, or more preferably between about 0.2 and 0.4%. The total amount of glycated-lysine residues in the oral dose should be about 0.3 grams. Preferably, a urine sample is collected before consumption of the glycated-lysine  
35 source, then at one, three and five hours, or such other appropriate times as may be warranted by the

- 40 -

individual clinical situation.

The 3DG and 3DF levels in these urine samples are measured and the ratios of these metabolites calculated. The particular methodology  
5 utilized in this measurement is not essential to the practice of this invention. The GC method described in Example 5, below, may be utilized, if desired. Alternatively, colorimetric or immunological assay methods can be used, as will be apparent to those  
10 skilled in the art.

It is clear that the major risk factor faced by diabetics is glycemic control, as was clearly demonstrated by the recently completed Diabetes Control and Complications Trial. However, the  
15 incidence of diabetic complications cannot be explained solely by blood sugar levels; a fairly wide scatter is seen when the incidence of diabetic complications is compared to historical blood sugar levels.

One method for determining that subset of  
20 the diabetic population which is most at risk for developing diabetic complications is a particularly significant aspect of the present invention. This method involves the measurement of FL, 3DG and 3DF  
25 levels before and, optimally, after ingesting a source of glycated lysine.

For example, normal subjects have a fasted 3DG to 3DF ratio in urine of about .025, whereas diabetics have higher ratios, which may be up to five  
30 fold higher, or more. This is borne out by the data in Figure 7, which shows that normoglycemics have a 3DG/3DF ratio of 0.025 (1/39.77) with quite tight scatter around this value, whereas diabetics have a more than 2 fold higher average ratio (average 0.069)  
35 with much more scatter around the average.

As demonstrated herein, diabetics have

- 41 -

increased production of 3DG. Therefore, resistance to diabetic complications requires highly efficient removal of this toxic metabolite. The ratio of 3DG to 3DF, calculated by the method described herein, allows one to assess the efficiency of the 3DG detoxification pathways. Those individuals with low ratio will be generally resistant to developing diabetic complications. Individuals with higher ratios, including ratios contained within the normal range, are more at risk, while individuals with elevated ratios above the normal range are particularly at risk for developing these complications.

Recent measurements of fructoselysine (FL) in the plasma and urine of four different rat strains have demonstrated considerable variability in the manner in which their respective kidneys process FL in blood. In two of the four strains (Long Evans, Brown Norway) virtually all of the FL filtered by the kidney appeared in the urine based upon ratios of this compound and its metabolites with creatinine. With the other two strains (Sprague Dawley, Fischer) 10-20% of the FL in the plasma appeared in the urine, based on comparisons with creatinine filtration. These measurements strongly suggest a major variability in FL processing in the mammalian kidney. Given what is known about the functional equivalence of rodent and human kidneys, it is reasonable to assume a similar variation in FL processing will exist among humans. Since FL is the primary input to the fructoselysine recovery pathway, the entire pathway is likely to be substantially stimulated in those humans in whom a large amount of FL is absorbed from the ultrafiltrate, leading to the high local levels of 3-deoxyglucosone (3DG) in the kidney, as well as systemically throughout the body. This observation may serve as the basis of a diagnostic test in which the comparison

- 42 -

of a sample of plasma or serum contemporaneously obtained with a urine sample would determine the flux of FL into the kidney, and the fraction of that flux which appears in the urine. Those individuals in whom  
5 this ratio is substantially lower than one (1) would then be at risk for developing a variety of kidney pathologies including, but not limited to, diabetic nephropathy, kidney failure in old age and kidney carcinoma.

10           Therapeutic efficacy of the kinase inhibitors of the invention can be easily and safely determined using a test of the lysine recovery pathway. The test protocol is identical to the one presented immediately above, with the exception that  
15 urinary fructoselysine levels are measured in addition to urinary 3DG and 3DF levels. It is useful to conduct this test both before and after initiating FL3P kinase inhibitor therapy. The urine levels of 3DG and 3DF are summed at each time point and compared  
20 to the levels of fructose-lysine measured in the same sample.

          The peak levels of 3DG and 3DF found in urine following ingestion of food rich in glycated-lysine residues are derived from the activity  
25 of the lysine recovery pathway. The ratio of the concentration of these metabolites to unreacted fructose-lysine (which is a normal component of human urine) reflects the activity of this pathway. Inhibition of the lysine recovery pathway will cause a  
30 decrease in the amount of 3DG and 3DF excreted, and an increase in the excreted levels of fructose-lysine. Thus, therapeutic efficacy of a kinase inhibitor can be quantitated by measuring the decrease of the (3DG + 3DF)/fructose-lysine ratio following initiation of  
35 therapy. It is noteworthy that urine volume or metabolite concentrations are not a factor in

- 43 -

interpreting this assay, as only a ratio of metabolites is considered.

It will be appreciated from the foregoing disclosure that orally digested food containing high concentrations of glycated-lysine residues will lead to the production of kidney and serum 3DG. It is reasonable to caution individuals at risk for kidney disease, for example diabetics, to avoid food with these high concentrations. Concentrations of glycated-lysine residues can be measured using a wide variety of methods. One such measurement method is described in Example 4, below. However, any suitable measurement methodology that accurately determines the levels of glycated-lysine residues can be substituted in place of the assay method exemplified below. Examples of assay methods specifically contemplated include but are not limited to colorimetric and immulogical methods.

Regardless of the method of measurement employed, it is within the scope of the present invention to determine the content of glycated-lysine residues in prepared foods and to apprise individuals at risk for developing kidney dysfunction of these determinations, so that such individuals may refrain from ingesting foods high in glycated-lysine content.

The following examples are provided to describe the invention in further detail. These examples are provided for illustrative purposes only, and should in no way be construed as limiting the invention. All temperatures given in the examples are in degrees centigrade unless otherwise indicated.

- 44 -

**EXAMPLE 1**

**ISOLATION AND IDENTIFICATION OF FL3P:** A  $^{31}\text{P}$  NMR analysis of a perchloric acid extract of diabetic rat kidneys showed a new sugar monophosphate resonance at 6.24 ppm which is not observed in non-kidney tissue and is present at greatly reduced levels in non-diabetic kidney. The compound responsible for the observed resonance was isolated by chromatography of the extract on a microcrystalline cellulose column using 1-butanol-acetic acid-water (5:2:3) as eluent. The structure was determined by proton 2D COSY to be fructose-lysine 3-phosphate. This was later confirmed by injecting animals with FL, prepared as previously described (Finot and Mauson, *Helv. Chim. Acta*, 52: 1488 (1969)), and showing direct phosphorylation to FL3P. Using FL specifically deuterated in position-3 confirmed the position of the phosphate at carbon-3. This was performed by analyzing the  $^{31}\text{P}$  NMR spectra both coupled and decoupled. The normal P-O-C-H coupling produces a doublet in FL3P with a J value of 10.3 Hz, whereas P-O-C-D has no coupling and produces a singlet both coupled and decoupled, as was found for 3-deuterated FL3P. A unique property of FL3P is that when treated with sodium borohydride it is converted into two new resonances at 5.85 and 5.95 ppm, which correspond to mannitol and sorbitol-lysine 3-phosphates.

**EXAMPLE 2**

**SYNTHESIS OF FL3P:** 1 mmol of dibenzyl-glucose 3-phosphate and 0.25 mmol of  $\alpha$ -carbobenzoxyl-lysine was refluxed in 50 ml of MeOH for 3 hours. The solution was diluted with 100 ml water and chromatographed on a Dow-50 column (2.5 x 20 cm) in the pyridinium form and eluted first with water (200 ml) and then with 600 ml buffer (0.1M pyridine and

- 45 -

0.3M acetic acid). The target compound eluted at the end of the water wash and the beginning of the buffer wash. Removal of the cbz and benzyl blocking groups with 5% Pd/C at 20 psi of hydrogen gave FL3P in 6%  
5 yield.

### EXAMPLE 3

ENZYMATIC PRODUCTION OF FL3P FROM FL AND ATP  
AND ASSAY FOR SCREENING INHIBITORS: Initially <sup>31</sup>P NMR  
10 was used to demonstrate kinase activity in the kidney cortex. A 3 g. sample of fresh pig kidney cortex was homogenized in 9 ml. of 50 mM Tris·HCl containing 150 mM KCl, 5 mM DTT, 15 mM MgCl<sub>2</sub>, pH 7.5. This was centrifuged at 10,000 g for 30 minutes, and then the  
15 supernate centrifuged at 100,000 g for 60 minutes. Ammonium sulfate was added to 60% saturation. After 1 hour at 4° the precipitate was collected by centrifugation and dissolved in 5 ml. of original buffer. A 2 ml aliquot of this solution was incubated  
20 with 10 mM ATP and 10 mM of FL (prepared as in Example 1, above) for 2 hours at 37°. The reaction was quenched with 300 uL of perchloric acid, centrifuged to remove protein, and desalted on a column of Sephadex G 10 (5 x 10 cm). <sup>31</sup>P NMR analysis of the  
25 reaction mixture detected formation of FL3P.

Based on the proof of kinase activity thus obtained, a radioactive assay was developed. This assay was designed to take advantage of the lack of binding to Dow-1 anion exchange resin by FL3P. This  
30 characteristic of FL3P was discovered during efforts to isolate it. Since most phosphates bind to this resin, it was suspected that the bulk of all compounds that react with ATP as well as any excess ATP would be bound, leaving FL3P in solution. The first step was  
35 to determine the amount of resin required to remove the ATP in the assay. This was accomplished by

- 46 -

pipetting the mixture into a suspension of 200 mg. of Dow-1 in 0.9 ml H<sub>2</sub>O, vortexing and centrifuging to pack the resin. From this 0.8 ml. of supernate was pipetted onto 200 mg. of fresh dry resin, vortexed and centrifuged. A 0.5 ml volume of supernate was pipetted into 10 ml of Ecoscint A and counted. Residual counts were 85 cpm. This procedure was used for the assay. The precipitate from 60% ammonium sulfate precipitation of the crude cortex homogenate was redissolved in the homogenate buffer at 4°. The assay contains 10 mM  $\gamma^{32}\text{P}$ -ATP (40,000 cpm), 10 mM FL, 150 mM KCl, 15 mM MgCl<sub>2</sub>, 5 mM DTT in 0.1 ml of 50 mM Tris·HCl, pH 7.5. The relationship between rates of FL3P production and enzyme concentration was determined using triplicate determinations with 1, 2 and 4 mg of protein for 30 minutes at 37°. Blanks run concurrently without FL were subtracted and the data recorded. The observed activity corresponds to an approximate FL3P synthesis rate of 20 nmols/hr./mg. protein.

#### EXAMPLE 4

##### INHIBITION OF THE FORMATION OF 3-DEOXYGLUCOSONE BY MEGLUMINE AND VARIOUS POLYOLLYSINES

###### a. General polyollysine synthesis.

The sugar (11 mmols),  $\alpha$ -carbobenzoxy-lysine (10 mmols) and NaBH<sub>3</sub>CN (15 mmols) were dissolved in 50 ml of MeOH-H<sub>2</sub>O (3:2) and stirred at 25° for 18 hours. The solution was treated with an excess of Dow-50 (H) ion exchange resin to decompose excess NaBH<sub>3</sub>CN. This mixture (liquid plus resin) was transferred onto a Dow-50 (H) column (2.5 x 15 cm) and washed well with water to remove excess sugar and boric acid. The carbobenzoxy-polyollysine was eluted with 5% NH<sub>4</sub> OH. The residue obtained upon evaporation was dissolved in water-methanol (9:1) and reduced with



- 47 -

hydrogen gas (20 psi) using a 10% palladium on charcoal catalyst. Filtration and evaporation yields the polyolllysine.

5       b.   Experimental protocol for reduction of urinary and plasma 3-deoxyglucosone by sorbitollysine, mannitollysine and galactitollysine.

Urine was collected from six rats for three hours. A plasma sample was also obtained. The animals were then given 10  $\mu$ moles of either  
10   sorbitollysine, mannitollysine, or galactitollysine by intraperitoneal injection. Urine was collected for another three hours, and a plasma sample obtained at the end of the three hours.

3-deoxyglucosone was measured in these  
15   samples, as described in Example 5, below, and variable volumes were normalized to creatinine. The average reduction of urinary 3-deoxyglucosone was 50% by sorbitollysine, 35% by mannitollysine and 35% by galactitollysine. Plasma 3-deoxyglucosone was reduced  
20   40% by sorbitollysine, 58% by mannitollysine and 50% by galactitollysine.

c.   Use of meglumine to reduce urinary 3-deoxyglucosone.

Three rats were treated as in b),  
25   immediately above, except meglumine (100  $\mu$ moles) was injected intraperitoneally instead of the above-mentioned lysine derivatives. Three hours after the injection the average 3-deoxyglucosone concentrations in the urine were decreased 42%.

30

#### EXAMPLE 5

ELEVATION OF URINARY FL, 3DG AND 3DF IN HUMANS FOLLOWING INGESTION OF GLYCATED PROTEIN:

a.   Preparation of glycated protein  
35   containing food product: 260 g. of casein, 120 g. of glucose and 720 ml. of water were mixed to give a

- 48 -

homogeneous mixture. This mixture was transferred to a metal plate and cooked at 65° for 68 hours. The resulting cake was then pulverized to a course powder.

5 This powder contained 60% protein as determined by the Kjeldahl procedure.

b. Measurement of glycated lysine content: 1 g of the powder prepared as in step a., above, was hydrolyzed by refluxing with 6N HCl for 20 hours. The resulting solution was adjusted to pH 1.8 with NaOH  
10 solution and diluted to 100 ml. The fructoselysine content was measured on an amino acid analyzer as furosine, the product obtained from acid hydrolysis of fructoselysine. In this way, it was determined that the cake contained 5.5% (w/w) fructoselysine.

15 c. Experimental protocol: Volunteers spent two days on a fructoselysine-free diet and then consumed 22.5 g of the food product prepared as described herein, thus effectively receiving a 2 g. dose of fructoselysine. Urine was collected at 2 hour  
20 intervals for 14 hours and a final collection was made at 24 hours.

d. Measurement of FL, 3DG and 3DF in urine: FL was measured by HPLC with a Waters 996 diode Array using a Waters C18 Free Amino Acid column  
25 at 46° and a gradient elution system of acetonitrile-methyl alcohol-water (45:15:40) into acetonitrile-sodium acetate-water (6:2:92) at 1 ml./min. Quantitation employed an internal standard of meglumine.

30 3DF was measured by HPLC after deionization of the sample. Analyses were performed on a Dionex DX-500 HPLC system employing a PA1 column (Dionex) and eluting with 32 mM sodium hydroxide at 1 ml./min. Quantitation was performed from standard curves  
35 obtained daily with synthetic 3DF.

3DG was measured by GC-MS after deionization

- 49 -

of the sample. 3DG was derivatized with a 10-fold excess of diaminonaphthalene in PBS. Ethyl acetate extraction gave a salt free fraction which was converted to the trimethyl silyl ethers with Tri-Sil (Pierce). Analysis was performed on a Hewlett-Packard 5890 selected ion monitoring GC-MS system. GC was performed on a fused silica capillary column (DB-5, 25 mx.25 mm) using the following temperature program: injector port 250°, initial column temperature 150° which is held for 1 minute, then increased to 290° at 16°/minute and held for 15 minutes. Quantitation of 3DG employed selected ion monitoring using an internal standard of U-13C-3DG.

The graph shown in Figure 3 represents production of FL, 3DF and 3DG in the urine of one volunteer after consuming the glycated protein. The rapid appearance of all three metabolites is clearly evident. Both 3DF and 3DG show a slight elevation even after twenty-four hours.

The graph shown in Figure 4 represents the formation of 3DF in each of the members of a seven person test group. A similar pattern was seen in all cases. As appears in Figure 4, 3DF excretion peaks about 4 hours after the FL bolus and a slight elevation of 3DF is noticeable even 24 h after the bolus.

#### EXAMPLE 6

**FEEDING EXPERIMENT:** N-acetyl- $\beta$ -glucosaminidase (NAGase) is an enzyme excreted into the urine in elevated concentration in diabetics. It is thought to be an early marker of tubular damage, but the pathogenesis of increased NAGase in urine is not well understood. The increased urinary output of NAGase in diabetics has been proposed to be due to activation of lysosomes in proximal tubules induced by

- 50 -

diabetes with an increased output into the urine rather than destruction of cells.

The results obtained in this example show that in all comparisons 3DF and NAGase levels are elevated in the experimental group relative to the control. Thus, animals fed glycated protein excrete excess NAGase into their urine, similar to results obtained with diabetics. There is an approximate 50% increase in NAGase output compared with control animals. These animals also have a five-fold increase in urine 3DF compared with controls. Urinary 3DF correlates extremely well with 3DG, as can be seen in Figures 5 and 6. Both compounds appear to be removed from the plasma at the glomerular filtration rate, with no reabsorption.

#### EXAMPLE 7

**SDS GEL OF KIDNEY PROTEINS:** Two rats were injected daily with 5  $\mu$ moles. of either FL or mannitol (used as a control) for 5 days. The animals were sacrificed and the kidneys removed and dissected into the cortex and medulla. Tissues were homogenized in 5 volumes of 50 mM Tris·HCl containing 150 mM KCl, 15 mM  $MgCl_2$  and 5 mM DTT, pH 7.5. Cellular debris was removed by centrifugation at 10,000 g for 15 minutes, and the supernate was then centrifuged at 150,000 g for 70 minutes. The soluble proteins were analyzed by SDS PAGE on 12% polyacrylamide gels as well as on 4-15 and 10-20% gradient gels. In all cases, lower molecular weight bands were missing or visually reduced from the kidney extract of the animal injected with FL when compared with the animal injected with mannitol.

35

- 51 -

**EXAMPLE 8****SYNTHESIS OF 3-O-METHYLFRUCTOSE LYSINE:**

A suspension of 19.4 g (0.1 mol) of anhydrous 3-O-methyl glucose and 1 g of sodium bisulfite in 30 ml of methanol and 15 ml of glycerol was refluxed for 30 minutes, followed by the addition of 0.035 mol of  $\alpha$ -carbobenzoxy-lysine and 4 ml of acetic acid. This solution was refluxed for 3 hours. The solution was treated with 1 volume of water and chromatographed on a Dowex-50 column (4x50 cm) in the pyridinium form, and eluted first with water and then with pyridinium acetate. Fractions containing the pure material were combined and evaporated. The resulting material was dissolved in 50 ml of water-methanol (9:1) and reduced with hydrogen gas (20 psi) using a 10% palladium on charcoal catalyst. Filtration and evaporation gave 3-O-methyl-fructoselysine.

Other specific compounds having the structure of formula (I), above, may be made e.g. by glycation of a selected nitrogen- or oxygen-containing starting material, which maybe an amino acid, polyaminoacid, peptide or the like, with a glycating agent, such as fructose, which may be chemically modified, if desired, according to procedures well know to those skilled in the art.

**EXAMPLE 9****ADDITIONAL ASSAY FOR FL3P KINASE ACTIVITY:****a. Preparation of Stock Solutions:**

An assay buffer solution was prepared which was 100 mM HEPES pH 8.0, 10 mM ATP, 2 mM  $MgCl_2$ , 5 mM DTT, 0.5 mM PMSF. A fructosyl-spermine stock solution was prepared which was 2 mM fructosyl-spermine Hcl. A spermine control solution was prepared which was 2 mM spermine Hcl.

- 52 -

**b. Synthesis of Fructosyl-spermine:**

Synthesis of fructosyl-spermine was performed by an adaptation of a known procedure (J. Hodge and B. Fisher, Methods Carbohydr. Chem., 2: 99-107 (1963)).

5 A mixture of spermine (500 mg), glucose (500 mg) and sodium pyrosulfite (80 mg) was prepared in a molar ratio of 8:4:1 (spermine:glucose:pyrosulfite) in 50 ml of methanol-water (1:1) and refluxed for 12 hours. The product was diluted to 200 ml with water and  
10 loaded onto a DOW-50 column (5x90 cm). The unreacted glucose was removed by 2 column volumes of water and the product and unreacted spermine were removed with 0.1 M  $\text{NH}_4\text{OH}$ . Pooled peak fractions of the product were lyophilized and concentration of fructosyl-spermine  
15 was determined by measuring the integral of the C-2 fructosyl peak in a quantitative  $^{13}\text{C}$  NMR spectrum of the product (NMR data collected with a  $45^\circ$  pulse, a 10 second relaxation delay and without NOE decoupling).

**c. Assay of Kinase for Purification:**

20 An incubation mixture was prepared including 10  $\mu\text{l}$  of the enzyme preparation, 10  $\mu\text{l}$  of assay buffer, 1.0  $\mu\text{Ci}$  of  $^{32}\text{P}$  ATP, 10  $\mu\text{l}$  of fructosyl-spermine stock solution and 70  $\mu\text{l}$  of water and incubated at  $37^\circ\text{C}$  for 1 hour. At the end of the incubation 90  $\mu\text{l}$   
25 (2x45 $\mu\text{l}$ ) of the sample is spotted onto two 2.5 cm diameter cellulose phosphate disks (Whatman P-81) and allowed to dry. The disks were washed extensively with water. After drying, the disks were placed in scintillation vials and counted.

30 Each enzyme fraction was assayed in duplicate with an appropriate spermine control.

- 53 -

**EXAMPLE 10****KIDNEY PATHOLOGY OBSERVED IN TEST****ANIMALS ON GLYCATED PROTEIN DIET**

Three rats were maintained on a glycated  
5 protein diet (20% total protein; 3% glycated) for 8  
months and compared to 9 rats of the same age  
maintained on a control diet. The primary finding was  
a substantial increase in damaged glomeruli in the  
animals on the glycated diet. Typical lesions  
10 observed in these animals were segmental sclerosis of  
the glomerular tuft with adhesion to Bowman's capsule,  
tubular metaplasia of the parietal epithelium and  
interstitial fibrosis. All three of the animals on the  
glycated protein diet, and only one of the animals on  
15 the control diet showed more than 13% damaged  
glomeruli. The probability of this happening by chance  
is less than 2%. In addition to the pathology  
observed in the glomeruli, a number of hylinated casts  
within tubules were observed. More of these were  
20 found in animals on the glycated diet, although these  
were not quantitated. Increased levels of NAGase were  
also observed in the animals on the glycated diet.

From the results of this experiment, the  
glycated diet appeared to cause the test animals to  
25 develop a series of histological lesions similar to  
those seen in the diabetic kidney.

**EXAMPLE 11****30 EFFECTS OF GLYCATED DIETS ON PREGNANCY**

In a preliminary experiment, 5 mice pairs  
were placed on a glycated diet (18% total protein; 3%  
glycated) and bred six times over a period of 7  
months. The resulting six pregnancies produced the  
35 following live pups; 17, 23, 13, 0, 3 and 0. In view  
of this sharp drop in live pups after the third

- 54 -

breeding, two cohorts of ten pairs each were put on either a glycated diet (13% total protein; 3% glycated) or a control diet (13% total protein; 0% glycated). Thus far, the two groups of pups have  
5 been bred four times obtaining similar results in both groups. The first pregnancy produced 49/20 (glycated/control) pups; the second, 18/41; the third 37/27; and the fourth 20/33. The fifth pregnancy is currently underway. The mice pairs have been tested  
10 for hyperglycemia. The blood glucose levels are 120 and 112 mg/dl in the experimental and control groups, respectively.

Preliminary measurements of the 3DF levels in the mice urine indicate, as expected, a substantial  
15 elevation (approximately 5-10 fold) of the systemic 3DF when on the glycated diet described herein.

#### EXAMPLE 12

##### CARCINOGENIC EFFECTS OF FRUCTOSELYSINE PATHWAY

20 To investigate the carcinogenic potential of metabolites formed in the fructoselysine pathway, experiments have been conducted on a strain of rats with a high susceptibility to kidney carcinomas. Four rats were put on a glycated protein diet and three  
25 rats on a control diet. After ten weeks on the diet, the animals were sacrificed and their kidneys examined. In all four animals on the diet, kidney carcinomas of size greater than 1mm were found, whereas no lesions this large were found in the  
30 control animals. The probability of this happening by chance is less than 2%. The data show that the elevated 3DG levels caused by the excess fructoselysine coming from the glycated protein in the animals diet found in the kidney tubular cells (known  
35 to be the cell of origin of most kidney carcinomas) can interact with the cellular DNA leading to a



- 55 -

variety of mutogenic and ultimately carcinogenic events. The possibility exists that this process is important in the development of human cancers in the kidney and elsewhere.

5

While certain embodiments of the present invention have been described and/or exemplified above, various other embodiments will be apparent to those skilled in the art from the foregoing disclosure. The present invention is, therefore, not limited to the particular embodiments described and/or exemplified, but is capable of consideration variation and modification without departure from the scope of the appended claims.

15

TABLE A

<u>Compound Name</u>	<u>X</u>	<u>R</u>	<u>R<sub>1</sub></u>	<u>Y</u>	<u>Z</u>
3-O-methylfructose lysine	-N-H	<sup>a</sup>   (CH <sub>2</sub> ) <sub>4</sub>   H-C-NH <sub>2</sub>   COO-	 CHOH   CHOH   CH <sub>2</sub> OH	 C=O 	-O-CH <sub>3</sub>
galactitol lysine	do	do	do	 H-C-OH 	-OH
3-deoxy sorbitol lysine	do	do	do	do	-H
3-deoxy-3-fluoro- xylitol lysine	do	do	 CHOH   CH <sub>2</sub> OH	do	-F
3-deoxy-3-cyano sorbitol lysine	do	do	 CHOH   CHOH   CH <sub>2</sub> OH	do	-C≡N

- 57 -

3-carboxy xyulose lysine	do	do	$\begin{array}{c}   \\ \text{CHOH} \\   \\ \text{CH}_2\text{OH} \end{array}$	$\begin{array}{c}   \\ \text{C=O} \\   \end{array}$	-COO-
3-sulfonic acid fructose gaba	do	<sup>b</sup> $\begin{array}{c}   \\ (\text{CH}_2)_3 \\   \\ \text{COO-} \end{array}$	$\begin{array}{c}   \\ \text{CHOH} \\   \\ \text{CHOH} \\   \\ \text{CH}_2\text{OH} \end{array}$	do	$\begin{array}{c} \text{O} \\    \\ \text{-S-O-} \\   \\ \text{O-} \end{array}$
1,3-dideoxy-3-fluoro- tagatose morpholine		morpholine	do	do	F
3-deoxy-sedoheptitol spermine	-N-CH <sub>3</sub>	<sup>c</sup> $\begin{array}{c}   \\ (\text{CH}_2)_3 \\   \\ \text{NH} \\   \\ (\text{CH}_2)_4 \\   \\ \text{NH} \\   \\ (\text{CH}_2)_3 \\   \\ \text{NH}_2 \end{array}$	$\begin{array}{c}   \\ \text{CHOH} \\   \\ \text{CHOH} \\   \\ \text{CHOH} \\   \\ \text{CH}_2\text{OH} \end{array}$	$\begin{array}{c}   \\ \text{H-C-OH} \\   \end{array}$	H

a - lysine residue  
b - γ-amino butyric acid residue  
c - spermine residue

- 58 -

## WHAT IS CLAIMED IS:

1. A compound having enzyme inhibitory activity, said compound being effective to inhibit the enzymatic conversion of fructose-lysine to fructose-lysine-3-phosphate, said activity being determined by an assay method comprising providing an aqueous solution containing pre-determined amounts of fructose-lysine, adenosine triphosphate, a source of fructose-lysine-3-phosphate kinase and said compound, subjecting said solution to conditions promoting the formation of fructose-lysine-3-phosphate and adenosine diphosphate as products resulting from the interaction of said kinase, said fructose-lysine and said adenosine triphosphate, and measuring the production of at least one of said products, said compound reducing the amount of said products, as compared to an aqueous solution of the same relative amounts of fructose-lysine, adenosine triphosphate and source of fructose-lysine-3-phosphate kinase, without the addition of said compound.

2. A compound, according to claim 1, wherein said source of fructose-lysine-3-phosphate kinase is kidney tissue.

3. A compound, according to claim 1, wherein said source of fructose-lysine-3-phosphate kinase is red blood cells or their progenitors.

4. A compound, according to claim 1, wherein said source of fructose-lysine-3-phosphate kinase is peripheral nerve tissue.

- 59 -

5. A compound, according to claim 1,  
wherein said source of fructose-lysine-3-phosphate  
kinase is lens tissue.


5 6. A compound according to claim 1,  
wherein said source of fructose-lysine-3-phosphate is  
pancreatic tissue.

7. A compound according to claim 1,  
10 wherein said compound exhibits competitive or non-  
competitive enzyme inhibition and has an inhibition  
constant ( $K_i$ ) of less than about 1 mM.

8. A compound according to claim 1 further  
15 having:

- (i) a molecular weight of less than  
about 2,000 Daltons;
- (ii) solubility in physiological saline  
or serum greater than or equal to 10  $\mu$ M; and
- 20 (iii) retention of at least 50% of its  
enzyme inhibition activity after incubation in  
physiological saline or serum for at least one hour.

9. A compound having the structural  
25 formula:



35

wherein X is -NR'- or -O-, R' being selected  
from the group consisting of H, and linear or branched  
chain alkyl group ( $\text{C}_1$ - $\text{C}_4$ ) and an unsubstituted or  
substituted aryl group ( $\text{C}_6$ - $\text{C}_{10}$ ) or aralkyl group ( $\text{C}_7$ -

- 60 -

$C_{10}$ ); R is a substituent selected from the group consisting of H, an amino acid residue, a polyaminoacid residue, a peptide chain, a linear or branched chain aliphatic group ( $C_1-C_8$ ), which is  
 5 unsubstituted or substituted with at least one nitrogen or oxygen-containing substituent, a linear or branched chain aliphatic group ( $C_1-C_8$ ), which is unsubstituted or substituted with at least one nitrogen- or oxygen-containing substituent and  
 10 interrupted by at least one -O-, -NH-, or -NR"-moiety, R" being linear or branched chain alkyl ( $C_1-C_6$ ) and an unsubstituted or substituted aryl group ( $C_6-C_{10}$ ) or aralkyl group ( $C_7-C_{10}$ ), with the proviso that when X represents -NR'-, R and R', together with the  
 15 nitrogen atom to which they are attached, may also represent a substituted or unsubstituted heterocyclic ring having from 5 to 7 ring atoms, with at least one of nitrogen and oxygen being the only heteroatoms in said ring, said aryl group ( $C_6-C_{10}$ ) or aralkyl group  
 20 ( $C_7-C_{10}$ ), and said heterocyclic ring substituents being selected from the group consisting of H, alkyl ( $C_1-C_6$ ), halogen,  $CF_3$ , CN,  $NO_2$  and -O-alkyl ( $C_1-C_6$ );  
 $R_1$  is a polyol moiety having 1 to 4 linear carbon atoms, Y is either a carbonyl moiety

25  $\begin{array}{c} | \\ (C=O) \text{ or a hydroxymethylene moiety } (H-C-OH) \\ | \end{array}$ ; Z is

selected from the group consisting of -H, -O-alkyl ( $C_1-C_6$ ), -halogen - $CF_3$ , -CN, -COOH and - $SO_3H_2$ ; and the  
 30 isomers and pharmaceutically acceptable salts of said compound.

10. A pharmaceutical preparation for  
 35 preventing, reducing or delaying the onset of diabetic complications in a diabetic patient, comprising, as an active agent, a compound according to claim 1 and a

- 61 -

pharmaceutically acceptable vehicle.

11. A pharmaceutically preparation  
according to claim 10 further comprising an anti-  
5 hypertensive drug and a supplement active agent.

12. A pharmaceutical preparation according  
to claim 10 in liquid form.

10 13. A pharmaceutical preparation according  
to claim 12 wherein said pharmaceutically acceptable  
vehicle is a liquid in which said active agent is  
soluble.

15 14. A pharmaceutical preparation according  
to claim 10 in tablet form.

20 15. A pharmaceutical preparation according  
to claim 14, wherein said tablet has a time-release  
coating.

25 16. A pharmaceutical preparation according  
to claim 14, wherein said tablet has an enteric  
coating.

30 17. A method for preventing, reducing or  
delaying the onset of diabetic complications in a  
patient at risk of developing said complications, said  
method comprising administering to said patient a  
compound which is effective to inhibit the enzymatic  
conversion of fructose-lysine to fructose-lysine-3-  
phosphate, in an amount sufficient to inhibit said  
conversion.

35

- 62 -

18. A method according to claim 17, wherein said compound has the structural formula:



wherein X is -NR'- or -O-, R' being selected from the group consisting of H, and linear or branched chain alkyl group (C<sub>1</sub>-C<sub>4</sub>) and an unsubstituted or substituted aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>); R is a substituent selected from the group consisting of H, an amino acid residue, a polyaminoacid residue, a peptide chain, a linear or branched chain aliphatic group (C<sub>1</sub>-C<sub>8</sub>), which is unsubstituted or substituted with at least one nitrogen or oxygen-containing substituent, a linear or branched chain aliphatic group (C<sub>1</sub>-C<sub>8</sub>), which is unsubstituted or substituted with at least one nitrogen- or oxygen-containing substituent and interrupted by at least one -O-, -NH-, or -NR"- moiety, R" being linear or branched chain alkyl (C<sub>1</sub>-C<sub>6</sub>) and an unsubstituted or substituted aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>), with the proviso that when X represents -NR'-, R and R', together with the nitrogen atom to which they are attached, may also represent a substituted or unsubstituted heterocyclic ring having from 5 to 7 ring atoms, with at least one of nitrogen and oxygen being the only heteroatoms in said ring, said aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>) and said heterocyclic ring substituents being selected from the group consisting of H, alkyl (C<sub>1</sub>-C<sub>6</sub>), halogen, CF<sub>3</sub>, CN, NO<sub>2</sub> and -O-alkyl (C<sub>1</sub>-C<sub>6</sub>); R<sub>1</sub> is a polyol moiety having 1



- 63 -

to 4 linear carbon atoms, Y is either a carbonyl moiety

5         $\begin{array}{c} | \\ (C=O) \\ | \end{array}$  or a hydroxymethylene moiety  $\begin{array}{c} | \\ (H-C-OH) \\ | \end{array}$ ; Z is

selected from the group consisting of -H, -OH, -O-alkyl ( $C_1-C_6$ ), -halogen - $CF_3$ , -CN, -COOH and - $SO_3H_2$ , and the isomers and pharmaceutically acceptable salts of  
10        said compound.

19. A method as claimed in claim 18, wherein said compound is at least one selected from the group consisting of meglumine, sorbitollysine,  
15        mannitollysine and galactitollysine.

20. A method according to claim 17, wherein said compound is administered in conjunction with an anti-hypertensive drug as a supplement active agent.  
20

21. A method according to claim 17, wherein said diabetes-associated pathologic condition is selected from the group consisting of diabetic nephropathy, diabetic retinopathy or diabetic  
25        peripheral neuropathy.

22. A method according to claim 17, wherein said compound is orally administered.

30        23. A method for assessing a diabetic patient's risk of experiencing a diabetes-associated pathologic condition, said method comprising administering to said patient a source of glycated-lysine residues in an amount providing at least about  
35        0.05 to about 0.3 grams of said glycated-lysine residues per kilogram of body weight and measuring the ratio of 3-deoxyglucosone to 3-deoxyfructose in at

- 64 -

least one biological sample obtained from said patient, with reference to the ratio of 3-deoxyglucosone to 3-deoxyfructose in an individual having no clinical symptoms of diabetes, a higher  
5 ratio of 3-deoxyglucosone to 3-deoxyfructose in said diabetic patient, in comparison to said asymptomatic individual being indicative that said diabetic patient is at higher risk of experiencing said diabetes-associated pathologic condition.

10

24. A method according to claim 23, wherein said diabetes-associated pathologic condition is selected from the group consisting of diabetic nephropathy, diabetic retinopathy or diabetic  
15 peripheral neuropathy.

25. A method according to claim 23, wherein said source of glycated-lysine residues is orally administered to said diabetic patient.

20

26. A method according to claim 23, wherein said biological sample is urine.

27. A method for assessing a diabetic  
25 patient's risk of experiencing a diabetes-associated pathologic condition, said method comprising measuring the ratio of 3-deoxyglucosone to 3-deoxyfructose in at least one biological sample obtained from said patient after a period of fasting, with reference to the ratio  
30 of 3DG to 3DF in a fasting individual having no clinical symptoms of diabetes, a higher ratio of 3-deoxyglucosone to 3-deoxyfructose in said diabetic patient being indicative that said diabetic patient is at higher risk of experiencing said diabetes-associated pathologic condition.  
35

- 65 -

28. A method according to claim 27, wherein  
said diabetes-associated pathologic condition is  
selected from the group consisting of diabetic  
nephropathy, diabetic retinopathy or diabetic  
5 peripheral neuropathy.

29. A method according to claim 27, wherein  
said source of glycated-lysine residues is orally  
administered to said diabetic patient.

10

30. A method according to claim 27, wherein  
said biological sample is urine.

31. A method for assessing the efficacy of  
15 therapeutic intervention in preventing diabetic  
complications, said method comprising measuring the  
concentration of 3-deoxyglucosone, 3-deoxyfructose and  
fructose-lysine in biological samples obtained from  
said diabetic patient, both before and after  
20 initiation of said therapeutic intervention, comparing  
the sum of said 3-deoxyglucosone and 3-deoxyfructose  
concentrations to the concentration of fructose-lysine  
in said samples, a decrease in the sum of 3-  
deoxyglucosone and 3-deoxyfructose concentrations  
25 relative to the fructose-lysine concentration in said  
biological sample taken after initiation of  
therapeutic intervention, as compared to the  
biological sample taken before initiation of said  
therapeutic intervention, being indicative of the  
30 efficacy of said therapeutic intervention.

32. A method according to claim 31, wherein  
said biological sample is urine.

35

- 66 -

33. A method according to claim 31, wherein said biological samples are obtained after a period of fasting.

5                   34. A method according to claim 31, wherein said biological samples are obtained following oral administration of a source of glycated lysine containing from 0.05 to about 0.3 of said glycated lysine per kilogram of body weight.

10                   35. A method for apprising a diabetic person of the potential of a packaged food product to contribute to the development of a diabetic-associated pathologic condition, comprising measuring the content  
15 of glycated-lysine residues in said food product and providing the result of said measurement on the package of said food product or in a publication intended for use by diabetics.

20                   36. A method for preventing a pathological condition in a patient, caused by the formation of AGE-proteins, said method comprising administering to said patient a therapeutically effective amount of a compound that inhibits production of 3-deoxyglucosone  
25 by said patient.

37. A method as claimed in claim 36, wherein said pathological condition is selected from the group consisting of hypertension, stroke,  
30 neurodegenerative disorders, e.g., senile demential of the Alzheimers type, circulatory disease, atherosclerosis, osteoarthritis, cataracts.

- 67 -


38. A method as claimed in claim 36,  
wherein said compound is of the formula:



wherein X is -NR'- or -O-, R' being selected from the group consisting of H, and linear or branched chain alkyl group (C<sub>1</sub>-C<sub>4</sub>) and an unsubstituted or substituted aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>); R is a substituent selected from the group consisting of H, an amino acid residue, a polyaminoacid residue, a peptide chain, a linear or branched chain aliphatic group (C<sub>1</sub>-C<sub>8</sub>), which is unsubstituted or substituted with at least one nitrogen or oxygen-containing substituent, a linear or branched chain aliphatic group (C<sub>1</sub>-C<sub>8</sub>), which is unsubstituted or substituted with at least one nitrogen- or oxygen-containing substituent and interrupted by at least one -O-, -NH-, or -NR''- moiety, R'' being linear or branched chain alkyl (C<sub>1</sub>-C<sub>6</sub>) and an unsubstituted or substituted aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>), with the proviso that when X represents -NR'-, R and R', together with the nitrogen atom to which they are attached, may also represent a substituted or unsubstituted heterocyclic ring having from 5 to 7 ring atoms, with at least one of nitrogen and oxygen being the only heteroatoms in said ring, said aryl group (C<sub>6</sub>-C<sub>10</sub>) or aralkyl group (C<sub>7</sub>-C<sub>10</sub>) and said heterocyclic ring substituents being selected from the group consisting of H, alkyl (C<sub>1</sub>-C<sub>6</sub>), halogen, CF<sub>3</sub>, CN, NO<sub>2</sub> and -O-alkyl (C<sub>1</sub>-C<sub>6</sub>); R<sub>1</sub> is a polyol moiety having 1

- 68 -

to 4 linear carbon atoms, Y is either a carbonyl moiety




selected from the group consisting of -H, -OH, -O-alkyl (C<sub>1</sub>-C<sub>6</sub>), -halogen -CF<sub>3</sub>, -CN, -COOH and -SO<sub>3</sub>H<sub>2</sub>, and the isomers and pharmaceutically acceptable salts of  
10      said compound.

39. A method as claimed in claim 38, wherein said compound is at least one selected from the group consisting of meglumine, sorbitollysine,  
15      mannitollysine and galactitollysine.

40. A method for inducing a pathological condition in a test animal, said pathological condition being selected from the group consisting of  
20      diabetic nephropathy, diabetic neuropathy, diabetic macroangiopathy, diabetic retinopathy, cardiovascular disease, neurodegenerative disease, insulin-dependent diabetes, diabetes-related birth defects and cancer, said method comprising feeding to said test animal a  
25      glycated protein diet in an amount and for a time sufficient to maintain the 3DG content of a biological fluid of said test animal relative to the 3DG content of a biological fluid from the same species of animal fed a diet substantially free of said glycated  
30      protein.

35



**FIG. 1**

2/6




FIG. 2



3/6




FIG. 4

4/6




FIG. 3



FIG. 5




FIG. 6

6/6




FIG. 7A




FIG. 7B

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/02192

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/01, 31/015, 31/70

US CL :514/24, 25, 54, 762

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/24, 25, 54, 762

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database Medline on STN, US National Library of Medicine, (Bethesda, MD, USA), No. 97104279, FOU DA, S.I. 'Effect of Lipopolysaccharide on Mitogen-activated Protein Kinases and Cytosolic Phospholipase A2', abstract, Biochemical Journal, June 1995.	1-22
A	Database EMBASE on STN, No. 93202080, BARES, R. 'Pancreatic cancer detected by position emission tomography with 18F-labelled deoxyglucose: Method and first results', abstract, Nucl. Med. Comm., 1993.	1-40
A	Database EMBASE on STN, No. 85042856, UCHIDA, K. 'Altered bile acid metabolism in nonobese, spontaneously diabetic (NOD) mice', abstract, Diabetes, 1985.	1-40



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 MARCH 1998

Date of mailing of the international search report

20 MAY 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

D. MARGARET M. MACH

Telephone No. (703) 308-1235

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/02192

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database Medline on STN, US National Library of Medicine, (Bethesda, MD, USA), No. 95277969, FOURNIER, N., 'Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high-density lipoproteins (HDL)', abstract, Clinica Chimica Acta, 1995.	1-40
A	Database Medline on STN, US National Library of Medicine, (Bethesda, MD, USA), No. 94314984, KAWAMURA, M> 'Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway', abstract, Journal of Clinical Investigation, 1994.	1-40
A	Database Medline on STN, US National Library of Medicine, (Bethesda, MD, USA), No. 90271410, SUZUKI, S. "Assay of glycated fibrinogen in plasma as an indicator of blood glucose control", abstract, Rinsho Byori Japanese Journal of Clinical Pathology, 1990.	1-40
A	Database EMBASE on STN, No. 97270221, AOKI, Y. 'Levels of fructosyllysine in collagen are low compared with the loss of lysine in diabetic rats: Involvement of oxidation in increased cross-linking', abstract, Clinical and Experimental Pharmacology and Physiology, 1997.	1-40
A	Database Medline on STN, US National Library of Medicine, (Bethesda, MD, USA), No. 97197246, WELLS-KNECHT, K.J. 'New biomarkabstract of Maillard reaction damage to proteins', abstract, Nephrology, Dialysis, Transplantation, 1996.	1-40